We are currently conducting the following trials :
.png)
Respiratory syncytial virus (RSV) is a contagious virus that infects the respiratory tract. It's common in children and adults, but can be especially serious for infants, the elderly, and people with weakened immune systems. Symptoms can include but not limited to Runny nose, Coughing, Sneezing, Fever, Decreased appetite, Wheezing, Irritability, Decreased activity, and Breathing difficulties.
Hepatitis Delta virus (HDV) is the causative agent of chronic hepatitis D (CHD), the most severe form of viral hepatitis. At least 12 million individuals worldwide (or 5% of all people with chronic hepatitis B [CHB]) have CHD, but this may be an underestimate due to suboptimal testing/reporting (Stockdale 2020). Infection with HDV is dependent on the presence of HBV infection, as it uses HBV-encoded envelope proteins (hepatitis B surface antigen [HBsAg]) for infection and replication (Farci 2012). HDV infection can occur either simultaneously with HBV or, more commonly, as a superinfection in patients already chronically infected with HBV. Relative to CHB infection alone, CHD coinfection is associated with more severe liver disease, causing faster progression to cirrhosis, hepatocellular carcinoma (HCC), and liver failure (Fattovich 1987, Romeo 2009).
This is a decentralized study to evaluate the efficacy and safety of study inhaler taken as needed, for up to 12 months. Participants 12 years of age and older with asthma will be recruited with all visits conducted virtually.
.png)
A migraine day is defined as a calendar day (12:00am to 11:59pm) in which the subject experiences a migraine attack that starts, ends or recurs within 24 hours and lasts for ≥1 hour (if untreated) or ≥30 minutes (if interrupted with rescue medication). Pain persisting for more than 1 calendar day (≥24 hours) after initial onset will be considered as a new, distinct headache day. Monthly migraine days is defined as the number of migraine days within 28 days or 4 weeks.
This pediatric study is intended to confirm safety in infants between 12 weeks to < 12 years of age and to bridge immunogenicity between infants/children and adults (> 18 years of age) enrolled in adult studies. It is necessary to demonstrate non-inferiority of the induced immune response in infants and children compared with that in adults to infer vaccine effectiveness in this age group.
If you’d like to register for any of the above studies, click the 'Join Our Patient List' button to register.
If you have any questions, please email:
info@clinicalresearchofcalifornia.com info@clinicalresearchofcalifornia.cominioiiiiiinfo@clinicalresearchofcalifornia.cominfo@clinicalresearchofcalifornia.com
.png)